The yeast 14-3-3 proteins BMH1 and BMH2 differentially regulate rapamycin-mediated transcription

Michael A. TREMBLEY*, Hunter L. BERRUS*, Jonathan R. WHICHER* and Emily L. HUMPHREY-DIXON*

*St. Lawrence University, 23 Romoda Drive, Canton, NY 13617, U.S.A.

Synopsis
14-3-3 proteins are highly conserved and have been found in all eukaryotic organisms investigated. They are involved in many varied cellular processes, and interact with hundreds of other proteins. Among many other roles in cells, yeast 14-3-3 proteins have been implicated in rapamycin-mediated cell signalling. We determined the transcription profiles of \( bmh1 \) and \( bmh2 \) yeast after treatment with rapamycin. We found that, under these conditions, \( BMH1 \) and \( BMH2 \) are required for rapamycin-induced regulation of distinct, but overlapping sets of genes. Both Bmh1 and Bmh2 associate with the promoters of at least some of these genes. \( BMH2 \), but not \( BMH1 \), attenuates the repression of genes involved in some functions required for ribosome biogenesis. \( BMH2 \) also attenuates the activation of genes sensitive to nitrogen catabolite repression.

Key words: 14-3-3, Bmh2, nitrogen catabolite repression (NCR), rapamycin, ribosome biogenesis, target of rapamycin (TOR)

INTRODUCTION
14-3-3 proteins are highly conserved and have been found in all eukaryotes investigated. They are involved in many varied cellular processes, and interact with hundreds of other proteins (reviewed in [1]). In yeast, there are two 14-3-3 proteins, Bmh1 and Bmh2, which share 93% amino acid identity [2–4]. In all genetic backgrounds tested, with the exception of \( /Sigma1 \), deletion of both \( BMH1 \) and \( BMH2 \) is lethal; however, deleting only one of these proteins has little effect on cell growth or viability [4,5]. They most commonly form homodimers or heterodimers [6]. They function primarily by binding to phosphorylated proteins [7], although other modes of binding have been reported [8–11].

Rapamycin is a small molecule that forms a complex with Fpr1 and the Tor (target of rapamycin) proteins, and thus blocks the TOR signalling pathway [12]. Treating yeast with rapamycin leads to a rapid and robust starvation response including changes in the expression of many yeast genes [13]. Among

many other roles in cells, yeast 14-3-3 proteins have been implicated in rapamycin-mediated cell signalling. Bertram et al. found that deleting the yeast 14-3-3 proteins makes cells more sensitive to rapamycin, whereas overexpression of \( BMH1 \) and \( BMH2 \) suppresses the inhibitory effects of rapamycin [14]. In addition, \( BMH2 \) has been shown to be involved in rapamycin-mediated signalling by binding to the transcription factors Msn2/Msn4 and Rtg3 and sequestering them in the cytoplasm. Upon treatment with rapamycin, the transcription factors are released and enter the nucleus [15,16].

The BMH proteins have been shown to localize to chromatin in yeast through several mechanisms including binding to histone H3 that is phosphorylated on serine 10 and acetylated on lysine 14 [17], binding to cruciform DNA [18], and associating with histone acetyltransferases and deacetylases [19]. 14-3-3 proteins have also been found to associate with G-box DNA-binding complexes in several plant species [20–22] and to regulate transcription in both mice and humans [10,23]. The apparent conditional association of 14-3-3 proteins with DNA positions the yeast 14-3-3 proteins as good candidates to regulate gene transcription under multiple growth conditions.
Previous studies have examined the transcription profile of yeast missing both of the BMH proteins under standard growth conditions [24,25]. These studies found that the BMH proteins are mainly required for the transcriptional regulation of genes involved in carbohydrate, lipid, and amino acid metabolism, the stress response, and protein synthesis and folding. They also regulate transporters of amino acids and Rtg3-regulated genes [24,25].

We determined the transcription profiles of bmh1 and bmh2 yeast after treatment with rapamycin. We found that, under these conditions, BMH1 and BMH2 are required for rapamycin-induced regulation of distinct, but overlapping sets of genes including those involved in ribosome biogenesis and nitrogen catabolite repression (NCR). We show that both Bmh1 and Bmh2 associate with the promoters of at least some of these genes.

MATERIALS AND METHODS

Yeast strains

The mutant strains bmh1 (MATa his3Δ1 leu2Δ0 met15Δ0 ura3Δ0 bmh1::KanMX) and bmh2 (MATa his3Δ1 leu2Δ0 met15Δ0 ura3Δ0 bmh2::KanMX) and the otherwise isogenic WT (wild-type) strain BY4741 (MATa his3Δ1 leu2Δ0 met15Δ0 ura3Δ0) were obtained from Research Genetics. Bmh1-3xHA (MATa BMH1-HA3::URA3::bmh1) and Bmh2–3xHA (MATa BMH2-HA3::URA3::bmh2) were a generous gift from M. P. Longhese (Università di Milano-Bicocca, Milano, Italy).

Transcription profiling

100 ml yeast were grown to an OD600 of ~1 in yeast extract/peptone/dextrose media and treated with either 50 nM rapamycin or a vehicle control (90 % (v/v) ethanol, 10 % (v/v) Tween-20) for 30 min. Approximately 50 mg of total RNA isolated from these cells was fluorescently labelled and hybridized to DNA microarrays spotted with 70 mer oligos representing all of the known reading frames in the yeast genome as previously described [26]. Microarrays were obtained from Genome Consortium for Active Teaching. These data represent an average of 3–5 independent experiments, each done in duplicate.

Chromatin immunoprecipitation

DNA associated with Bmh1 or Bmh2 was immunoprecipitated from 90 ml of yeast cells containing endogenously HA-tagged BMH1 or BMH2 grown to an OD600 of ~1.0, then treated for 30 min with either 50 nM rapamycin or a vehicle control. Cells were crosslinked and lysed as described [29]. The immunoprecipitation was carried out using 15 µl of anti-HA antibody (Millipore) as described [29]. Approximately 1/50 of the immunoprecipitation material, referred to as WCE (whole-cell extract) was reserved and treated exactly as the immunoprecipitated DNA.

Quantitative PCR

The promoters of selected genes were each amplified from approximately 1/30 of the immunoprecipitated material using Qiagen SYBR Green PCR mix in an Opticon 2 real-time PCR machine (Bio-Rad) according to the manufacturers’ instructions. The following primer pairs were used for quantitative PCR: NS2 promoter, 5′-CAAGGATCTTGATGTGCGATG-3′ and 5′-GTGCATCTTCATCCTGTCCTC-3′; NMD3 promoter, 5′-GGGATGAGAAAATCGGTGAAA-3′ and 5′-TATTGTATGTGACCGGCAAA-3′; NOG2 promoter, 5′-GTGCAATT-GCTCCCTCCTG-3′ and 5′-CGCTTCTTATATGGCCCCAAA-3′; GAP1 promoter, 5′-AAAGGAATAGGG-3′ and 5′-GAGTCAATGGGTA-3′; TUB2 promoter, 5′-GGCCCTAAGATGTA-3′ and 5′-GTGCTCTAGTCTGC-3′. Fold binding of Bmh1 and Bmh2 to gene promoters was determined using the Pfaffl method [28]. For each promoter examined, the coding region of TUB2 was used as the reference. Each fold-change in expression represents the average of 3–5 independent experiments, each done in duplicate.

RESULTS

BMH1 and BMH2 are required for the rapamycin-induced regulation of different sets of genes

To determine the roles of BMH1 and BMH2 in transcriptional regulation following rapamycin treatment, we used microarrays to examine relative levels of each yeast mRNA. We compared

© 2014 The Author(s) This is an Open Access article distributed under the terms of the Creative Commons Attribution Licence (CC-BY) (http://creativecommons.org/licenses/by/3.0/) which permits unrestricted use, distribution and reproduction in any medium, provided the original work is properly cited.
transcription. Indeed, we found that deleting either expression of genes (Figure 1, Supplementary Table S1 at http://www.bioscirep.org/bsr/034/bsr034e099add.htm). However, we also found that alters the rapamycin-induced transcription profile in similar ways, and they are required for both the activation and repression of many ribosome biogenesis genes. We selected three ribosome biogenesis genes, NSA2, NMD3 and NOG2, and used quantitative reverse-transcription PCR (RT-qPCR) to verify this observed decrease in repression (Figure 3A). We found that Bmh2, but not Bmh1, attenuates the repression of all of these genes following rapamycin treatment. Next, we wanted to know whether the transcriptional regulation of these genes by Bmh2 was direct or indirect. To do this, we used ChIP (chromatin immunoprecipitation) followed by qPCR. We found that Bmh2 associates with the promoters of these genes following rapamycin treatment (Figure 3B), suggesting that this is a direct effect.

**Bmh2 is required to attenuate the repression of ribosome biogenesis genes**

Treating yeast with rapamycin leads to a decrease in translation, which is caused in part by transcriptional down-regulation of genes involved in ribosome biogenesis [13]. Based on the microarray data, Bmh2 but not Bmh1 acts to decrease the repression of many ribosome biogenesis genes. We selected three ribosome biogenesis genes, NSA2, NMD3 and NOG2, and used quantitative reverse-transcription PCR (RT-qPCR) to verify this observed decrease in repression (Figure 3A). We found that Bmh2, but not Bmh1, attenuates the repression of all of these genes following rapamycin treatment. Next, we wanted to know whether the transcriptional regulation of these genes by Bmh2 was direct or indirect. To do this, we used ChIP (chromatin immunoprecipitation) followed by qPCR. We found that Bmh2 associates with the promoters of these genes following rapamycin treatment (Figure 3B), suggesting that this is a direct effect.

**Bmh2 is required to attenuate the activation of NCR genes**

The microarray data indicate that genes sensitive to NCR are more highly expressed in bmh2 mutants than in bmh1 mutants. These genes are activated to approximately the same extent in WT and bmh1 cells, but activated, on average, approximately 1.5-fold more in bmh2 mutants than in WT cells or bmh1 mutants. We examined the transcription of GAP1, an NCR gene, by quantitative RT-PCR to verify these microarray results. We found that Bmh2 attenuates the activation of GAP1 to a greater extent than does Bmh1 (Figure 4A), verifying our microarray data. Bmh2 binds to the promoter of GAP1 upon rapamycin treatment (figure 4B), suggesting that this is a direct effect.

**The yeast 14-3-3 proteins do not regulate each other's expression**

One possible explanation for our data is that the absence of one of the yeast 14-3-3 genes could lead to altered expression levels of the other 14-3-3 gene. To test this possibility, we examined the expression of Bmh1 and Bmh2 when the other
Figure 2  Gene ontology terms enriched (P < 10^{-4}) in the top 200 genes that are transcribed at lower levels in bmh1 cells or bmh2 cells than in WT cells following rapamycin treatment were determined

(A) Enriched gene ontology terms in both bmh1 and bmh2 cells, (B) enriched gene ontology terms in only bmh1 cells and (C) enriched gene ontology terms in bmh2. The per cent of the 200 genes that map to each term is represented in each gene ontology bar.
gests that while Bmh1 and Bmh2 have very similar sequences, have different subcellular localization patterns [32]. This sug-
transport of Pmp2 [31] and that the two yeast 14-3-3 proteins
that Bmh1, but not Bmh2 is required for the efficient forward
ent processes in cells. For example, previous results demonstrate
However, Bmh1 and Bmh2 appear to be required for some differ-
and Bmh2 performing different roles in regulating transcription.

To the best of our knowledge, this is the first report of Bmh1
and Bmh2 playing overlapping but distinct roles in regulating rapamycin-induced transcrip-
tional changes. Previous genome-wide studies of the effects
of yeast 14-3-3 proteins on transcription used systems in which
both BMH1 and BMH2 were inactivated, and looked only at
steady-state conditions [24,25]. We found some of the same gene
classes to be regulated by individual 14-3-3 proteins following
rapamycin treatment, but also identified new groups of genes that
require 14-3-3 proteins for transcriptional regulation following
rapamycin treatment.

Here, we present evidence that BMH1 and BMH2 play
overlapping but distinct roles in regulating rapamycin-mediated transcription. Previous genome-wide studies of the effects
of yeast 14-3-3 proteins on transcription used systems in which
both BMH1 and BMH2 were inactivated, and looked only at
steady-state conditions [24,25]. We found some of the same gene
classes to be regulated by individual 14-3-3 proteins following
rapamycin treatment, but also identified new groups of genes that
require 14-3-3 proteins for transcriptional regulation following
rapamycin treatment.

The best of our knowledge, this is the first report of Bmh1
and Bmh2 playing different roles in regulating transcription. However, Bmh1 and Bmh2 appear to be required for some differ-
ent processes in cells. For example, previous results demonstrate
that Bmh1, but not Bmh2 is required for the efficient forward
transport of Pmp2 [31] and that the two yeast 14-3-3 proteins
have different subcellular localization patterns [32]. This sug-
gests that while Bmh1 and Bmh2 have very similar sequences,
there is sufficient variability to allow them to perform unique functions.

We identified genes that are regulated by just Bmh1, just
Bmh2, or both Bmh1 and Bmh2 following rapamycin treatment. Genes that require one of the yeast 14-3-3 proteins but not the other for WT expression levels likely have a requirement for the corresponding 14-3-3 protein homodimer. Genes that have altered expression in both bmh1 and bmh2 mutants likely require a Bmh1/Bmh2 heterodimer for proper expression, or require a 14-3-3 protein to be present and are sensitive to changes in the overall levels of 14-3-3 proteins caused by deleting one of the iso-
forms. All three of these dimer types occur in vivo, with approx-
imately 65% of Bmh2 and 79% of Bmh1 occurring in homodi-
mers [33]. However, since there are approximately 3.3 copies of
Bmh1 for every copy of Bmh2, all three dimer types are likely to
be present in sufficient abundance to allow for functionality
[30,33].

Our data suggest that there is a stronger role for Bmh2
than Bmh1 in regulating rapamycin-mediated transcription. This
could be explained if there were higher levels of Bmh2 than
Bmh1. In fact, the opposite result has been found [30]. This sug-
gests that our results are not due to a dosage effect. We also show
that our results are not a due to deleting one of the 14-3-3 iso-
forms altering the expression levels of the other isoform. In order
to control transcription, however, proteins must be localized to the
nucleus. Under steady-state conditions, Bmh2 is localized to both
the cytoplasm and the nucleus, whereas Bmh1 is localized only
to the cytoplasm [32]. Since we have identified a role for Bmh1 in

14-3-3 gene was deleted both in untreated cells and in cells
treated with rapamycin. We found that deleting one 14-3-3 gene
does not lead to changes in the expression of the other 14-3-3
gene (Figure 5).

**DISCUSSION**

Figure 3  **BMH2 but not BMH1 acts at the promoters of ribosome biogenesis genes to attenuate their repression following rapamycin treatment**

(A) Quantitative RT-PCR was used to determine the transcriptional effect of treating the indicated yeast strain (WT, bmh1 and bmh2) with rapamycin. Each data point represents the abundance of NMD3, NSA2 and NOG2 RNA in rapamycin-treated cells compared with vehicle-treated cells, relative to the RNA levels of TUB2. Error bars indicate the standard error of the mean (n = 3). (B) ChIP followed by quantitative PCR was used to determine the extent to which Bmh1 and Bmh2 bind to the promoters of NMD3, NSA2 and NOG2. Each data point represents the fold enrichment of the indicated promoter after the immunoprecipitation compared with the whole cell extract, relative to the enrichment of the promoter of TUB2. Error bars indicate the standard error of the mean (n = 4).
regulating transcription, it is likely that there is at least a small amount of Bmh1 in the nucleus following rapamycin treatment. Bmh1 becomes localized to the nucleus upon DNA replication stress [34], suggesting that such a translocation is possible.

Our data suggest that Bmh2 is necessary for the regulation of gene classes including ribosome biogenesis genes and NCR genes. Bmh2 binding to the promoters of these genes increases following rapamycin treatment, suggesting that Bmh2 is directly regulating these genes. This regulation may be due to Bmh2 binding to either the DNA or other proteins in the promoters of these genes.

We found that both Bmh1 and Bmh2 act to moderate many of the transcriptional effects of rapamycin treatment, including the down-regulation of ribosome biogenesis genes and the up-regulation of NCR genes. This is consistent with Bertram et al. [14] who showed that the 14-3-3 proteins decrease rapamycin-induced growth suppression, and also with Wang et al. [35] who showed that deleting BMH1 extends lifespan by enhancing the stress response, and does so in part through interactions with the TOR pathway.

We found that Bmh2 attenuates the activation of NCR-sensitive genes. Following rapamycin treatment, the transcription factors Gln3 and Gat1 translocate into the nucleus and activate the transcription of these genes. It was previously determined that the yeast 14-3-3 proteins bind Gln3 and Gat1 [36], suggesting a potential mechanism for this effect.

**AUTHOR CONTRIBUTION**

Michael Trembley conducted the microarray experiments and some of the quantitative RT-PCR. Hunter Berrus, Jonathan Whicher and Emily Humphrey-Dixon conducted quantitative PCR and quantitative RT-PCR experiments. Data analysis was done by Michael Trembley, Hunter Berrus and Emily Humphrey-Dixon. The paper was written primarily by Emily Humphrey-Dixon and Michael Trembley.
ACKNOWLEDGEMENTS
We are grateful to the Genome Consortium for Active Teaching (GCAT), its Director Dr A. Malcolm Campbell, and to the National Science Foundation for support of GCAT.

FUNDING
This material is based upon the work supported by the National Science Foundation [grant number 0959713].

REFERENCES

1 van Heusden, G. and Steensma, H. (2006) Yeast 14-3-3 proteins. Yeast 23, 159–171
2 Geelperin, D., Weigle, J., Nelson, K., Roseboom, P. Irie, K., Matsumoto, K. and Lemmon, S. (1995) 14-3-3 proteins: potential roles in vesicular transport and ras signaling in Saccharomyces cerevisiae. Proc. Natl. Acad. Sci. U.S.A. 92, 11539–11543
3 van Heusden, G. P., Wenzel, T. J., Lagendijk, E. L., de Steensma, H. Y. and van den Berg, J. A. (1992) Characterization of the yeast BMH1 gene encoding a putative protein homologous to mammalian protein kinase II activators and protein kinase C inhibitors. FEBS Lett. 302, 145–150
4 van Heusden, G. P., Griffiths, D. J., Ford, J. C., Chin-A-Woeng, T. F., Schrader, P. A., Garr, A. M. and Steensma, H. Y. (1995) The 14-3-3 proteins encoded by the BMH1 and BMH2 genes are essential in the yeast Saccharomyces cerevisiae and can be replaced by a plant homologue. Eur. J. Biochem. 229, 45–53
5 Roberts, R. L., Mosch, H. U. and Fink, G. R. (1997) 14-3-3 proteins are essential for RAS/MAPK cascade signaling during pseudohyphal development in S. cerevisiae. Cell 89, 1055–1065
6 Pan, S., Sehnke, P. C., Ferl, R. J. and Gurlay, W. B. (1999) Specific interactions with TBP and TFII B in vitro suggest that 14-3-3 proteins may participate in the regulation of transcription when part of a DNA binding complex. Plant Cell 11, 1591–1602
7 Muslim, A. J., Tanner, J. W., Allen, P. M. and Shaw, A. S. (1996) Interaction of 14-3-3 with signaling proteins is mediated by the recognition of phosphoserine. Cell 84, 889–897
8 Petosa, C., Masters, S. C., Bankston, L. A., Pohl, J., Wang, B., Fu, H. and Liddington, R. C. (1998) 14-3-3-beta binds a phosphorylated ras peptide and an unphosphorylated peptide via its conserved amphipathic groove. J. Biol. Chem. 273, 16305–16310
9 Gu, M. and Du, X. (1998) A novel ligand-binding site in the zeta-form 14-3-3 protein recognizing the platelet glycoprotein ibalpha and distinct from the c-raf-binding site. J. Biol. Chem. 273, 33465–33471
10 Wakiu, H., Wright, A. P., Gustafsson, J. Z. and Zilius, J. C. (1997) Interaction of the ligand-activated glucocorticoid receptor with the 14-3-3 eto protein. J. Biol. Chem. 272, 8153–8166
11 Matto-Yelin, M., Aitken, A. and Ravid, S. (1997) 14-3-3 inhibits the interaction of TBP and TFIIB with ARS307. J. Biol. Chem. 273, 25356–25363
12 Zheng, X. F., Foverino, D., Chen, J., Crabtree, G. R. and Schreiber, S. L. (1995) TOR kinase domains are required for two distinct functions, only one of which is inhibited by rapamycin. Cell 82, 121–130
13 Shamji, A. F., Kuruvilla, F. G. and Schreiber, S. L. (2000) Partitioning the transcriptional program induced by rapamycin among the effectors of the tor proteins. Curr. Biol. 10, 1574–1581
14 Bertram, P. G., Zeng, C., Thorson, J., Shaw, A. S. and Zheng, X. F. (1998) The 14-3-3 proteins positively regulate rapamycin-sensitive signaling. Curr. Biol. 8, 1259–1267
15 Beck, T. and Hall, M. N. (1999) The TOR signaling pathway controls nuclear localization of nutrient-regulated transcription factors. Nature 402, 689–692
16 van Heusden, G. P. and Steensma, H. Y. (2001) 14-3-3 proteins are essential for regulation of RTG3-dependent transcription in Saccharomyces cerevisiae. Yeast 18, 1479–1491
17 Walter, W., Cynes, D., Tang, Y., Marmorstein, R., Mellor, J. and Berger, S. L. (2008) 14-3-3 interaction with histone H3 involves a dual modification pattern of phosphoacetylation. Mol. Cell. Biol. 28, 2840–2849
18 Callejo, M., Alvarez, D., Price, G. B. and Zannis-Hadjopoulos, M. (2002) The 14-3-3 protein homologues from Saccharomyces cerevisiae, Bmh1p and Bmh2p, have cruciform DNA-binding activity and associate in vivo with ARS307. J. Biol. Chem. 277, 38416–38423
19 Lottersberger, F., Panza, A., Lucchini, G. and Longhese, M. P. (2007) Functional and physical interactions between yeast 14-3-3 proteins, acetyltransferases, and deacetylases in response to DNA replication perturbations. Mol. Cell. Biol. 27, 3266–3281
20 de Vetten, N. C., Lu, G. and Ferl, R. J. (1992) A maize protein associated with the G-box binding complex has homology to brain regulatory proteins. Plant Cell 4, 1295–1307
21 Lu, G., DeLisle, A. J., de Vetten, N. C. and Ferl, R. J. (1992) Brain proteins in plants: an arabidopsis homolog to neurotransmitter pathway activators is part of a DNA binding complex. Proc. Natl. Acad. Sci. U.S.A. 89, 11490–11494
22 Schultz, T. F., Medina, J., Hill, A. and Quatrano, R. S. (1998) 14-3-3 proteins are part of an abscisic acid-VIVIPAROUS1 (VP1) response complex in the em promoter and interact with VP1 and EmBP1. Plant Cell 10, 837–847
23 Tang, S. J., Suen, T. C., McInnes, R. R. and Buchwald, M. (1998) Association of the TLX2 homedomain and 14-3-3-beta signaling proteins. J. Biol. Chem. 273, 25356–25363
24 Bruckmann, A., Steensma, H. Y., Teixeira De Mattos, M. J. and Van Heusden, G. P. (2004) Regulation of transcription by Saccharomyces cerevisiae 14-3-3 proteins. Biochem. J. 382, 867–875
25 Ichimura, T., Kubota, H., Goma, T., Mizushima, N., Osushima, Y., Iwago, M., Kakuchi, K., Shikhar, H. U., Shinkawa, T., Taoka, M. et al. (2004) Transcriptomic and proteomic analysis of a 14-3-3 gene-deficient yeast. Biochemistry 43, 6149–6158
26 Humphrey, E. L., Shamji, A. F., Bernstein, B. E. and Schreiber, S. L. (2004) Rpd3p relocation mediates a transcriptional response to rapamycin in yeast. Chem. Biol. 11, 295–299
27 Eisen, M. B., Spellman, P. T., Brown, P. O. and Botstein, D. (1998) Cluster analysis and display of genome-wide expression patterns. Proc. Natl. Acad. Sci. U.S.A. 95, 14863–14868
28 Pfaffl, M. W. (2001) A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res. 29, e45
29 Bernstein, B. E., Humphrey, E. L., Erlich, R. L., Schneider, R., Bouman, P., Liu, J. S., Kouzarides, T. and Schreiber, S. L. (2002) Methylation of histone H3 lys 4 in coding regions of active genes. Proc. Natl. Acad. Sci. U.S.A. 99, 8865–8700
30 Ghaemmaghami, S., Huh, W. K., Bower, K., Howson, R. W., Belle, A., Dephoure, N., O’Shea, E. K. and Weissman, J. S. (2003) Global analysis of protein expression in yeast. Nature 425, 737–741
31 Michelsen, K., Mrowiec, T. E., Duderstadt, K. E., Frey, S., Minor, D. L., Mayer, M. P. and Schwappach, B. (2006) A multimeric membrane protein reveals 14-3-3 isoform specificity in forward transport in yeast. Traffic 7, 903–916
32 Huh, W. K., Falvo, J. V., Gerke, L. C., Carroll, A. S., Howson, R. W., Weissman, J. S. and O’Shea, E. K. (2003) Global analysis of protein localization in budding yeast. Nature 425, 686–691
33 Chaudhri, M., Scarambino, M. and Aitken, A. (2003) Mammalian and yeast 14-3-3 isoforms form distinct patterns of dimers in vivo. Biochem. Biophys. Res. Commun. 300, 679–685
34 Take, J. M., Yamada, H., Nakano, T., Saito, Y., Battelli, P., Rinke, M., Costanzo, M., Jascho, H., Hendry, J. A., Ou, J., Moffat, J., Boone, C., Davis, T. N., Nislow, C. and Brown, G. W. (2012) Dissecting DNA damage response pathways by analysing protein localization and abundance changes during DNA replication stress. Nat. Cell Biol. 14, 966–976
35 Wang, C., Skinner, C., Easlon, E. and Lin, S. J. (2009) Deleting the 14-3-3 protein Bmh1 extends life span in *Saccharomyces cerevisiae* by increasing stress response. Genetics 183, 1373–1384.

36 Kakiuchi, K., Yamauchi, Y., Taoka, M., Iwago, M., Fujita, T., Ito, T., Song, S. Y., Sakai, A., Isobe, T. and Ichimura, T. (2007) Proteomic analysis of in vivo 14-3-3 interactions in the yeast *Saccharomyces cerevisiae*. Biochemistry 46, 7781–7792.